Latest filing published 08 Jun 2023 for Satsuma Pharmaceuticals, Inc., €5.0M.
Filing timeline
BuySaleInsider track record
Closed purchases
Based on 3 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- -25.3%Entry US$38.74 · Close at T+365 US$28.93
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Rajeev M. Shah: trading record in brief
Rajeev M. Shah (board member) discloses dealings in 7 companies, chiefly Black Diamond Therapeutics, Inc., Satsuma Pharmaceuticals, Inc. and KALA BIO, Inc. In total, 38 filings cover trades dated from 31 October 2016 to 6 June 2023.
The open-market record is one-sided, with 14 purchases worth €166.5M and not one sale. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The rest of the record consists of 6 share grants.
A typical purchase (the median) is worth €12.5M. Clusters matter here: 11 out of 11 purchases overlapped with buying by a colleague within 30 days. Purchases made close together by different insiders form what is called a cluster. Ninety days after publication, 3 purchases show a median change of -0.6%, with the price up in 0% of them. They describe history only and say nothing certain about the share price ahead.
On 8 June 2023 came the latest disclosure, a transaction for €5.0M in Satsuma Pharmaceuticals, Inc. The most recent open-market purchase was published on 13 March 2020, 2,431 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Rajeev M. Shah
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 5,914,252 shares@ US$0.91100.0% of flowCommon Stock, $0.0001 par valueSEC:0000899243-23-014898:0
- 20,000 shares0Common StockSEC:0001415889-21-003125:0
- 443 shares@ US$24.01100.0% of flowCommon StockSEC:0001104659-21-070583:0
- 353,814 shares@ US$24.2629.8% of flowCommon StockSEC:0001104659-21-046615:0
- 443 shares@ US$24.010.0% of flowCommon StockSEC:0000899243-21-012956:0
- 4,938,282 shares@ US$3.70100.0% of flowCommon StockSEC:0001104659-20-135400:0
- 20,000 shares0Common StockSEC:0001104659-20-078330:0
- 4,858,260 shares@ US$48.00100.0% of flowCommon StockSEC:0001104659-20-042764:0
- 6,337,135 shares@ US$7.89Common StockSEC:0001104659-20-033392:0Canonical exit: 11 Jun 2020 (T+90)
- 785,658 shares@ US$19.0078.5% of flowCommon StockSEC:0000899243-20-003363:6Canonical exit: 3 May 2020 (T+90)
- 77,803 shares@ US$19.007.8% of flowCommon StockSEC:0000899243-20-003363:7Canonical exit: 3 May 2020 (T+90)
- 136,539 shares@ US$19.0013.6% of flowCommon StockSEC:0000899243-20-003363:8Canonical exit: 3 May 2020 (T+90)
- 186,749 sharesCommon StockSEC:0000899243-20-003363:2
- 181,783 sharesCommon StockSEC:0000899243-20-003363:3
- 70,770 sharesCommon StockSEC:0000899243-20-003363:4
- 30,526 sharesCommon StockSEC:0000899243-20-003363:5
- 956,723 sharesCommon StockSEC:0000899243-20-003363:0
- 163,353 sharesCommon StockSEC:0000899243-20-003363:1
- 1,642,879 sharesCommon Stock, $0.0001 par valueSEC:0000899243-19-023733:0
- 1,139,635 sharesCommon Stock, $0.0001 par valueSEC:0000899243-19-023733:1
- 365,530 sharesCommon Stock, $0.0001 par valueSEC:0000899243-19-023733:2
- 200,481 sharesCommon Stock, $0.0001 par valueSEC:0000899243-19-023733:3
- 1,140,946 shares@ US$15.0066.9% of flowCommon Stock, $0.0001 par valueSEC:0000899243-19-023733:4Canonical exit: 16 Dec 2019 (T+90)
- 192,387 shares@ US$15.0011.3% of flowCommon Stock, $0.0001 par valueSEC:0000899243-19-023733:5Canonical exit: 16 Dec 2019 (T+90)
- 1,881,720 shares@ US$4.6534.2% of flowCommon StockSEC:0001209191-19-043491:0
25 of 32 declarations
